Skip to main navigation menu Skip to main content Skip to site footer

Vol. 13 No. 5 (2026)
International Multidisciplinary Journal for Research & Development

Articles

ANALYSIS OF PRINCIPLES FOR IMPROVING OPTIMAL TREATMENT MEASURES FOR LIVER AND BILE DUCT DISEASES

Published 2026-05-26

  • Munira Amanovna Mamadjanova,
    • ,
  • Davronbek Salim oʻgʻli A'zamov,
    • ,
  • Zukhriddin Alisher oʻgʻli Oʻrishboev

Munira Amanovna Mamadjanova,
Department of the pharmacology of the Tashkent state medical university

Davronbek Salim oʻgʻli A'zamov,
Tashkent state medical university

Zukhriddin Alisher oʻgʻli Oʻrishboev
Tashkent state medical university

Abstract

A chronic autoimmune liver disease called primary biliary cholangitis (PBC) is characterized by the destruction of the bile duct, which results in fibrosis and cholestasis. There are still gaps in patient-centered care, therapy response evaluation, and diagnostic standardization despite therapeutic breakthroughs. The goal of this study was to optimize PBC management by using consensus-driven quality measures. 92 clinicians took part in two rounds of questionnaires that included patient-reported outcomes (PROs), follow-up criteria, therapeutic approaches, and diagnostic methods using the Delphi methodology. The RAND/UCLA technique was used to analyze appropriateness evaluations in order to get a consensus on important quality metrics.The suitability of non-invasive diagnostic techniques such abdominal ultrasound and Vibration-Controlled Transient Elastography (VCTE) for staging and tracking fibrosis in chronic cholestasis was widely agreed upon. Patients with compensated cirrhosis (Child-Pugh A) and inadequate response to UDCA were investigated for various treatment options; early initiation was considered appropriate in cases of UDCA intolerance or partial response. Consensus on genetic tests and liver biopsies varied, especially for patients lacking biochemical cholestasis, indicating areas that require more investigation. This study provides detailed suggestions on diagnostic procedures, therapy benchmarks, and follow-up requirements in order to establish practical quality measurements for PBC care. By filling in gaps in patient categorization, follow-up procedures, and tactics, these actions go above and beyond recommendations. Cost-effectiveness, non-invasive tool accessibility, and implementation issues including physician training and resource availability should all be covered in future studies.

 

Keywords

Primary biliary cholangitis (PBC), obeticholic acid (OCA), non-invasive diagnostic techniques, Delphi consensus process, quality metrics in PBC treatment.

PDF

References

  1. Alvaro D, Calvaruso V, Carbone M, Cazzagon N, Floreani A, Invernizzi P, Marzioni M, Pasqualetti P, Pennisi G, Toniutto P, Vespasiani-Gentilucci U, Craxì A. Quality Measures to Enhance the Management and Treatment of Primary Biliary Cholangitis: A Delphi Consensus Study. Liver Int. 2025 Jun;45(6):e70118. doi: 10.1111/liv.70118. Erratum in: Liver Int. 2025 Nov;45(11):e70400. doi: 10.1111/liv.70400.
  2. Aripov A.N., Aripov O.A., Akhundjanova L.L., Nabiev A.U., Nabieva D.A., & Khamroev T.T. (2022). Study the effect of yantacin on some indicators of cellular renewal and on the level of protein expression on rat hepatocytes in chronic heliotrine liver damage. International Journal of Medical Sciences And Clinical Research, 2(05), 06–13. https://doi.org/10.37547/ijmscr/Volume02Issue05-02.
  3. Aripov A. N, Akhunzhanova L. L, Nabiev A. U, Aripov A. O, Khamroev T. T.. Antifibrotic Efficacy of a New Phytocomposition of Essential Phospholipids with Glycyrrhizic Acid, Ecdysterone, Lycopene and Proanthacyanidin in Experimental Severe Chronic Hepatitis Compared with Phosphogliv. Biomed Pharmacol J 2023;16(3).Pages : 1815-1825. DOI : https://dx.doi.org/10.13005/bpj/2761
  4. Aripov A.N, Akhunjanova L.L, Khamroev T.T, Aripov Abdumalik Nigmatovich, Akhunjanova Lola Lazizovna, & Khamroev Tolmas Tolibovich. (2022). Differential Analysis of Chronic Toxic Hepatitis Caused by The Introduction of Heliotrin Solution in Various Ways. Texas Journal of Medical Science, 4, 58–62. Retrieved from https://zienjournals.com/index.php/tjms/article/view/670
  5. Rashidov S.Z., Rakhimboev S.D., Sanoev Z.I., Abdinazarov I.T., Khamroev T.T., Ismailova D.S., & Elmuradov B.J.. (2022). Study of psychoactive activity potassium salt 5-(o-aminophenyl)-1,3,4- oxadiazole-2-thion (D-361). International Journal of Medical Sciences And Clinical Research, 2(09), 1–5. https://doi.org/10.37547/ijmscr/Volume02Issue09-01
  6. Арипов А.Н., Арипов О.А., Ахунджанова Л.Л., Набиев А.Ў., Нишанбаев С.З., Набиева Д.А., Ҳамроев Т.Т. Тажриба шароитида сафорофлавонолозиднинг гепатотроп фаоллигини ўрганиш. Oriental Journal of Medicine and Pharmacology, 2(02), 55–64. https://doi.org/10.37547/supsci-ojmp-02-02-07
  7. Zakhidova L.T., Saidkhodjaeva D.M., Sanoev Z.I., Tukhtasheva V.F., Rakhmanova H.A.., Hamroyev T.T. Toxicological Characteristics Of N-Deacetyllappaconitine Under Chronic Administration In White Rats. The American Journal of Applied Sciences, 3(03), 34-41. https://doi.org/10.37547/tajas/Volume03Issue03-06
  8. Khamroev T.T., Sanoev Z.I., Rakhimboev S.D., Abdinazarov I.T., Rashidov S.Z. Effect of antiarrhythmic substance N – dezacetyllapoconitin on the central nervous system. ISJ Theoretical &Applied Science, 07 (99), 153-157. http://soi.org/1.1/TAS-07-99-31 Doi:https://dx.doi.org/10.15863
  9. Sanoev Z. I, Ismailova D. S, Rakhimboev S. D. O, Khamroev T, T, Elmuradov B. Z, Abdinazarov I. T, Rashidov S. Z. O. Synthesis and Research Anticonvulsant Activity of Annulated Triazolo-Thiadiazine Derivative in Laboratory Animals. Biomed Pharmacol J 2023;16(4). DOI : https://dx.doi.org/10.13005/bpj/2820
  10. Sokhib Rashidov Zamon oʻgʻli, Muslimakhon Kamolova Mirzokhidjon qizi, Ikhvoliddin Mirzaev Komiljon o‘g‘li, Nodira Pardaeva Botir qizi, Sevara Rakhmatullaeva Shukhrat qizi/. (2025). The importance of cardiotonic drugs in medical practice, the range of applications and the advantages of their use. International Journal of Cognitive Neuroscience and Psychology, 3(5), 95–100. Retrieved from https://medicaljournals.eu/index.php/IJCNP/article/view/1856
  11. Sanoev Zafar Isomiddinovich, Rashidov Sokhib Zamon ugli, Raximboev Sukhrob Davlatyor ugli, Abdinazarov Ibrokhim Tuychievich, Khamroev Tolmas Tolibovich, Ismailova Dilnoza Safaralievna, & Elmuradov Burkhon Juraevich. (2022). Research of Anticonvulsant Activity of Compound 5- (P-Aminophenyl) - 1,3,4-Oxadiazole-2-Thion. Texas Journal of Medical Science, 13, 17–21. Retrieved from https://zienjournals.com/index.php/tjms/article/view/2434
  12. Yu. R. Mirzaev, T. T. Khamroev, E. M. Ruzimov, B. N. Khandamov, & Sh. M. Adizov. (2022). Evaluation of the Effect on the Nervous System of Substances with an Alkaloid Structure Having Antitumor Activity. Journal Healthcare Treatment Development(JHTD) ISSN : 2799-1148, 2(06), 6–10. Retrieved from http://journal.hmjournals.com/index.php/JHTD/article/view/1577
  13. Aripov A.N., Aripov O.A., Akhunjanova L.L., Nabiev A.O., Nabieva D.A., & Khamroev T.T. (2022). Study the antifibrous efficacy of plant proanthocyanidin in rats with chronic heliotrine liver damage. Frontline Medical Sciences and Pharmaceutical Journal, 2(05), 16–25. https://doi.org/10.37547/medical-fmspj-02-05-03.
  14. Sokhib Rashidov Zamon oʻgʻli, Nilufar Ergasheva Agʼzamjon qizi, Elyor Zokirboyev Anvarjon o‘gli, Umidjon Akramov Abdusamad o‘g‘li, & Aziza Egamberdieva Farkhod qizi. (2025). Drugs That Increase the Tone of the Human Body and Pharmacological Characteristics of Immunodeficiency Agents. American Journal of Biomedicine and Pharmacy, 2(5), 300–306. Retrieved from https://biojournals.us/index.php/AJBP/article/view/1065
  15. Sokhib Rashidov Zamon oʻgʻli, Murodjon Nabiev Mahammadkarim o‘g‘li, Mo'tabar Yoqubjonova Khusanboy qizi, Shakhzodakhon Bekmurodova Poʻlatjon qizi, & Jumanazar To‘ychiev Saidqul o‘g‘li. (2025). Comparative Analysis of Drugs Used for Anemia and Drugs Storing Iron. Research Journal of Trauma and Disability Studies, 4(5), 190–195. Retrieved from https://journals.academiczone.net/index.php/rjtds/article/view/5141
  16. Sokhib Rashidov Zamon oʻgʻli, Shakhzoda Abduraimova Abdusattor qizi, Nigora Yusufjonova Mirrakhim qizi, Diyora Turdibekova Erkinjon qizi, & Makhsuma Dovutkho’jayeva Maqsudjonovna. (2025). Classification, Indications for Use, Range of Applications and Disadvantages of Medicines against Nematodes and Leishmania. Research Journal of Trauma and Disability Studies, 4(5), 196–201. Retrieved from https://journals.academiczone.net/index.php/rjtds/article/view/5142
  17. Sokhib Rashidov Zamon oʻgʻli, Nigora Yusufjonova Mirrakhim qizi, Diyora Turdibekova Erkinjon qizi, Makhsuma Dovutkho’jaeva Maqsudjonovna, Shakhzoda Abduraimova Abdusattor qizi, Analysis of the effect of medicines used in medical practice for various diseases on the fetus , european journal of modern medicine and practice: Vol. 5 No. 5 (2025) 342-347.
  18. Sokhib Rashidov Zamon oʻgʻli, Elyor Zokirboev Anvarjon ògli, Umidjon Akramov Abdusamad o‘g‘li, Aziza Egamberdiyeva Farkhod qizi, Munisa Qoʻshbekova Roʻzimbek qizi. (2025). Analysis of general and specific pharmacological properties of fat-soluble vitamins. International Journal of Cognitive Neuroscience and Psychology, 3(5), 101–106. Retrieved from https://medicaljournals.eu/index.php/IJCNP/article/view/1857
  19. Rajapaksha IG, Angus PW, Herath CB. Current therapies and novel approaches for biliary diseases. World J Gastrointest Pathophysiol. 2019 Jan 5;10(1):1-10. doi: 10.4291/wjgp.v10.i1.1.
  20. Choi, G., Jesudian, A.B. & Saab, S. Optimizing Care in Primary Biliary Cholangitis: Current Treatments and the Second-Line Decision. Dig Dis Sci (2025). https://doi.org/10.1007/s10620-025-09537-3
  21. Yoshida EM, Swain MG, Tsien C et al. Clinical characterization of patients with primary biliary cholangitis: a report from multiple Canadian centres. Can Liver J. 2022;5:372–387.
  22. Levy C, Bowlus CL. Primary biliary cholangitis: personalizing second-line therapies. Hepatology. 2024. https://doi.org/10.1097/hep.0000000000001166.
  23. Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, Shimizu M, Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. J Gastroenterol. 2021 Jul;56(7):593-619. doi: 10.1007/s00535-021-01788-x.

Downloads

Download data is not yet available.